Events & Presentations

Presentations
Date Title
Sep 18, 2017
Sep 10, 2017

Upcoming Events

Details on upcoming events are not yet available. Please click here to be notified of all upcoming events.

Archived Events
Date Details
Sep 18, 2017
10:30 AM ET
Ultragenyx Pharmaceutical Inc. Conference Call to Discuss the Proposed Offer to Acquire Dimension Therapeutics

Forward Looking Statements / Additional Information

Except for the historical information contained in the replay, the matters set forth in the replay, including statements of anticipated changes in the business environment in which Ultragenyx operates and in Ultragenyx’s future prospects or results, statements relating to Ultragenyx’s intentions, plans, hopes, beliefs, anticipations, expectations or predictions of its future, or statements relating to Ultragenyx’s offer and the potential benefits of a transaction with Dimension Therapeutics, Inc. (“Dimension”), are forward-looking statements. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, such as the regulatory approval process, the timing of our regulatory filings and other matters that could affect sufficiency of existing cash, cash equivalents and short-term investments to fund operations and the availability or commercial potential of our drug candidates. There is no assurance that the potential transaction will be consummated, and it is important to note that actual results could differ materially from those projected in such forward-looking statements. Ultragenyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Ultragenyx in general, see Ultragenyx's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on July 28, 2017, and its subsequent periodic reports filed with the SEC.

 

The tender offer referred to in the replay (an “Offer”) has not yet commenced. Accordingly, the replay is for informational purposes only and does not constitute an offer to purchase or a solicitation of an offer to sell any shares of Dimension common stock or any other securities. On the commencement date of any Offer, a tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and related materials, will be filed with the SEC by Ultragenyx and a wholly owned subsidiary.  The offer to purchase shares of Dimension common stock will only be made pursuant to the offer to purchase, letter of transmittal and related materials filed with the SEC by Ultragenyx as part of its Schedule TO. Investors and security holders are urged to read both the tender offer statement and any solicitation/recommendation statement filed by Dimension regarding the Offer, as they may be amended from time to time, when they become available, because they will contain important information about the Offer, including its terms and conditions, and should be read carefully before any decision is made with respect to the Offer. Investors and security holders may obtain free copies of these statements (when available) and other materials filed with the SEC at the website maintained by the SEC at www.sec.gov, or by directing requests for such materials to the information agent for the Offer, which will be named in the tender offer statement

Sep 12, 2017
10:00 AM ET
Morgan Stanley Global Healthcare Conference
Sep 8–11, 2017
ASBMR 2017 Annual Meeting
Sep 7, 2017
12:50 PM ET
Baird 2017 Global Healthcare Conference
Jul 27, 2017
5:00 PM ET
Second Quarter 2017 Financial Results and Corporate Update
Jun 14, 2017
3:20 PM PT
Goldman Sachs 38th Annual Global Healthcare Conference
Jun 8, 2017
2:30 PM ET
Jefferies 2017 Global Healthcare Conference
May 16, 2017
3:00 PM PT
Bank of America Merrill Lynch 2017 Healthcare Conference
May 4, 2017
5:00 PM ET
First Quarter 2017 Financial Results and Corporate Update
Apr 18, 2017
1:30 PM PT
Phase 3 Data Results for KRN23 (burosumab) in Adult XLH Patients
Mar 15, 2017
11:15 AM ET
Barclays Global Healthcare Conference
Mar 7, 2017
8:00 AM ET
Cowen and Company 37th Annual Health Care Conference
Feb 16, 2017
5:00 PM ET
Fourth Quarter 2016 Financial Results and Corporate Update
Feb 15, 2017
9:30 AM ET
Leerink Partners 6th Annual Global Healthcare Conference
Jan 10, 2017
7:30 AM PT
35th Annual J.P. Morgan Healthcare Conference
Sep 19, 2016
11:00 AM ET
Ultragenyx ASBMR Data Conference Call
Aug 8, 2016
5:00 PM ET
Second Quarter 2016 Financial Results and Corporate Update
Jul 14, 2016
2:00 PM PT
Phase 3 Data Results for rhGUS in MPS 7
May 9, 2016
5:00 PM ET
First Quarter 2016 Financial Results and Corporate Update
Feb 25, 2016
5:00 PM ET
Fourth Quarter and Full Year 2015 Financial Results and Corporate Update
= add file to Briefcase